Innoviva ROA 2004-2025 | INVA
Current and historical return on assets (ROA) values for Innoviva (INVA) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Innoviva ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2025-06-30 |
$0.04B |
$1.33B |
2.97% |
| 2025-03-31 |
$-0.06B |
$1.25B |
-4.87% |
| 2024-12-31 |
$0.02B |
$1.30B |
1.83% |
| 2024-09-30 |
$0.07B |
$1.23B |
5.23% |
| 2024-06-30 |
$0.15B |
$1.23B |
11.86% |
| 2024-03-31 |
$0.18B |
$1.27B |
15.11% |
| 2023-12-31 |
$0.18B |
$1.24B |
15.38% |
| 2023-09-30 |
$0.05B |
$1.19B |
4.29% |
| 2023-06-30 |
$0.23B |
$1.12B |
19.47% |
| 2023-03-31 |
$0.23B |
$1.13B |
19.39% |
| 2022-12-31 |
$0.22B |
$1.23B |
17.90% |
| 2022-09-30 |
$0.29B |
$1.33B |
26.05% |
| 2022-06-30 |
$0.10B |
$1.14B |
9.76% |
| 2022-03-31 |
$0.19B |
$1.11B |
20.17% |
| 2021-12-31 |
$0.27B |
$0.93B |
28.73% |
| 2021-09-30 |
$0.31B |
$0.89B |
32.84% |
| 2021-06-30 |
$0.27B |
$0.79B |
27.90% |
| 2021-03-31 |
$0.25B |
$1.09B |
26.02% |
| 2020-12-31 |
$0.22B |
$1.00B |
24.96% |
| 2020-09-30 |
$0.22B |
$0.92B |
26.06% |
| 2020-06-30 |
$0.23B |
$0.88B |
29.72% |
| 2020-03-31 |
$0.19B |
$0.79B |
26.70% |
| 2019-12-31 |
$0.16B |
$0.73B |
24.00% |
| 2019-09-30 |
$0.38B |
$0.68B |
61.24% |
| 2019-06-30 |
$0.38B |
$0.64B |
74.44% |
| 2019-03-31 |
$0.40B |
$0.59B |
91.17% |
| 2018-12-31 |
$0.40B |
$0.55B |
109.85% |
| 2018-09-30 |
$0.19B |
$0.28B |
60.27% |
| 2018-06-30 |
$0.17B |
$0.34B |
48.62% |
| 2018-03-31 |
$0.15B |
$0.28B |
41.79% |
| 2017-12-31 |
$0.13B |
$0.37B |
35.22% |
| 2017-09-30 |
$0.10B |
$0.39B |
26.34% |
| 2017-06-30 |
$0.09B |
$0.37B |
24.31% |
| 2017-03-31 |
$0.07B |
$0.39B |
18.95% |
| 2016-12-31 |
$0.06B |
$0.38B |
15.57% |
| 2016-09-30 |
$0.04B |
$0.37B |
9.83% |
| 2016-06-30 |
$0.02B |
$0.38B |
4.46% |
| 2016-03-31 |
$-0.01B |
$0.39B |
-1.18% |
| 2015-12-31 |
$-0.02B |
$0.41B |
-4.45% |
| 2015-09-30 |
$-0.04B |
$0.44B |
-8.37% |
| 2015-06-30 |
$-0.06B |
$0.46B |
-11.05% |
| 2015-03-31 |
$-0.11B |
$0.49B |
-20.64% |
| 2014-12-31 |
$-0.17B |
$0.52B |
-29.56% |
| 2014-09-30 |
$-0.20B |
$0.55B |
-33.20% |
| 2014-06-30 |
$-0.23B |
$0.61B |
-35.81% |
| 2014-03-31 |
$-0.20B |
$0.61B |
-31.57% |
| 2013-12-31 |
$-0.17B |
$0.68B |
-26.84% |
| 2013-09-30 |
$-0.15B |
$0.67B |
-27.18% |
| 2013-06-30 |
$-0.14B |
$0.60B |
-28.66% |
| 2013-03-31 |
$-0.14B |
$0.59B |
-32.11% |
| 2012-12-31 |
$-0.02B |
$0.37B |
-5.26% |
| 2012-09-30 |
$-0.02B |
$0.38B |
-7.62% |
| 2012-06-30 |
$-0.02B |
$0.40B |
-6.90% |
| 2012-03-31 |
$-0.01B |
$0.22B |
-3.01% |
| 2011-12-31 |
$-0.12B |
$0.26B |
-40.00% |
| 2011-09-30 |
$-0.10B |
$0.28B |
-31.82% |
| 2011-06-30 |
$-0.09B |
$0.30B |
-30.29% |
| 2011-03-31 |
$-0.08B |
$0.32B |
-30.80% |
| 2010-12-31 |
$-0.08B |
$0.33B |
-32.75% |
| 2010-09-30 |
$-0.09B |
$0.21B |
-39.73% |
| 2010-06-30 |
$-0.09B |
$0.23B |
-41.61% |
| 2010-03-31 |
$-0.09B |
$0.25B |
-43.41% |
| 2009-12-31 |
$-0.09B |
$0.18B |
-43.31% |
| 2009-09-30 |
$-0.08B |
$0.18B |
-37.62% |
| 2009-06-30 |
$-0.08B |
$0.21B |
-34.21% |
| 2009-03-31 |
$-0.08B |
$0.22B |
-33.64% |
| 2008-12-31 |
$-0.09B |
$0.24B |
-35.07% |
| 2008-09-30 |
$-0.11B |
$0.26B |
-44.49% |
| 2008-06-30 |
$-0.12B |
$0.28B |
-51.80% |
| 2008-03-31 |
$-0.14B |
$0.30B |
-64.44% |
| 2007-12-31 |
$-0.16B |
$0.16B |
-77.85% |
| 2007-09-30 |
$-0.16B |
$0.20B |
-71.54% |
| 2007-06-30 |
$-0.17B |
$0.21B |
-67.33% |
| 2007-03-31 |
$-0.17B |
$0.25B |
-59.23% |
| 2006-12-31 |
$-0.17B |
$0.26B |
-55.33% |
| 2006-09-30 |
$-0.17B |
$0.29B |
-58.47% |
| 2006-06-30 |
$-0.17B |
$0.32B |
-63.67% |
| 2006-03-31 |
$-0.16B |
$0.33B |
-65.51% |
| 2005-12-31 |
$-0.14B |
$0.23B |
-62.51% |
| 2005-09-30 |
$-0.13B |
$0.20B |
-53.28% |
| 2005-06-30 |
$-0.11B |
$0.23B |
-46.34% |
| 2005-03-31 |
$-0.11B |
$0.26B |
-59.73% |
| 2004-12-31 |
$-0.10B |
$0.29B |
-83.10% |
| 2004-09-30 |
$-0.09B |
$0.21B |
-175.61% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$0.953B |
$0.331B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
